 SAN DIEGO, Feb. 24, 2021 PRNewswire -- Halozyme Therapeutics, Inc. NASDAQ: HALO Halozyme or the Company, a leader in converting IV biologics to subcutaneous delivery, today announced the pricing of 700 million aggregate principal amount of its convertible senior notes due 2027... 